SCLP Immunobody Platform13 May 2020 22:46
Can anyone comment on similarities or differences in the approach of a US Company which has a platform which like SCLP is primarily aimed at Cancer Vax but being adapted to use vs Covid 19.I ask only to see if we can perhaps get a better valuation of done of potential here as a peer Company.
I would appreciate as unbiased a view as possible based on how they may or may not be different in Approach.Thanks in advance
PDS Biotechnology Corporation, a Delaware corporation (the “Company,” “PDS,” or the “combined company”), PDS is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. Our current development pipeline of cancer immunotherapy products and infectious disease vaccines is based on the Versamune® platform. Our immuno-oncology products can potentially be used as a component of combination products with other leading technologies to provide effective treatments across a range of cancer types, including Human Papillomavirus (HPV)-based cancers, melanoma, colorectal, lung, breast and prostate cancers or as monotherapies in early-stage disease. PDS is working to expand its infectious disease pandemic development program, including novel vaccines for COVID-19 and universal influenza, in addition to its previously announced tuberculosis development collaboration with Farmacore Biotechnology.
Sign In
Follow the stocks
